* Oncogene Science Inc., of Uniondale, N.Y., received programproject grant funding of $900,000 over three years from the NationalHeart, Lung and Blood Institute to discover and develop agentsuseful for sickle cell disease and B-thalassemia.
* SRI International, of Menlo Park, Calif., and Taiho PharmaceuticalCo. Ltd., of Tokyo, entered a research agreement to develop a newchemotherapy approach for breast cancer. The companies willdevelop and evaluate endocrine approaches for use in chemotherapyof estrogen-dependent breast cancer.
* GeneMedicine Inc., of The Woodlands, Texas, received five SmallBusiness Innovation Research grants, totaling $1.3 million, from theNational Institutes of Health in Bethesda, Md. The grants willsupport the company's development of non-viral gene therapy to treata variety of diseases.
* Genzyme Corp., of Cambridge, Mass., signed a three-yearCollaborative Research and Development Agreement with theNational Cancer Institute (NCI) to develop a gene therapy formetastatic melanoma. The effort will focus on using Genzyme'sadenoviral vectors to deliver genes for melanoma tumor antigens tostimulate a patient's immune system to attack the cancer cells. TwoPhase I trials of the treatment are under way and results are expectedin early 1997. The NCI is part of the National Institutes of Health inBethesda, Md.
* Isis Pharmaceuticals Inc., of Carlsbad, Calif., received $8.3 millionfrom Boehringer Ingelheim GmbH, of Ingelheim, Germany, as part oftheir 1995 collaboration to develop drugs that block cell adhesionmolecules linked to inflammatory diseases. The money is the firstpayment from a $40 million line of credit provided by Ingelheim toIsis to cover its portion of research and development expenses. Isishas the option of repaying the funds in cash or stock. One drugcandidate in the collaboration, Isis 2302, is an antisenseoligonucleotide in Phase II trials for five indications _ kidneytransplant rejection, rheumatoid arthritis, Crohn's disease, ulcerativecolitis and psoriasis. (See BioWorld Today, March 2, 1995, p. 1.)
* Rhone-Poulenc Rorer Inc., of Collegeville, Pa., received clearancein Brazil to market Rilutek (riluzole) for treatment of amyotrophiclateral sclerosis, known as Lou Gehrig's disease. The drug also isapproved in the U.S. and the European Union's 15 nations.
* The Liposome Company Inc., of Princeton, N.J., completed a callfor redemption of its 7.75 percent convertible exchangeable preferredstock. The company, which said substantially all preferred stock wasexchanged for common shares, issued 2.3 million new shares. TheLiposome Company has 36.6 million shares outstanding. It raised$65 million in the sale of the preferred stock. Officials said theconversion to common shares saves the firm $5.3 million in annualdividends paid on the preferred stock. (See BioWorld Today, Sept.17, 1996, p. 1.)
* Unigene Laboratories Inc., of Fairfield, N.J., raised $6.9 million ina private placement of common stock and warrants to institutionalinvestors. The company sold 3.94 million shares and warrants topurchase another 1.97 million shares at $3 per share. The privateplacement was managed by BT Securities Corp., a subsidiary ofBankers Trust New York Corp.
(c) 1997 American Health Consultants. All rights reserved.